{"protocolSection":{"identificationModule":{"nctId":"NCT00323869","orgStudyIdInfo":{"id":"IRB-03730"},"secondaryIdInfos":[{"id":"96655","type":"OTHER","domain":"Stanford IRB alternate number"},{"id":"AVF3576s"},{"id":"LUN0013","type":"OTHER","domain":"OnCore"},{"id":"NCT00323869","type":"OTHER","domain":"NCT number"}],"organization":{"fullName":"Stanford University","class":"OTHER"},"briefTitle":"Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer","officialTitle":"Phase II Trial of Bevacizumab in Combination With Gemcitabine and Carboplatin in Patients With Newly Diagnosed Non-Small Cell Lung Cancer (Excluding Squamous Cell Carcinoma)"},"statusModule":{"statusVerifiedDate":"2016-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-06"},"primaryCompletionDateStruct":{"date":"2013-10","type":"ACTUAL"},"completionDateStruct":{"date":"2013-10","type":"ACTUAL"},"studyFirstSubmitDate":"2006-05-08","studyFirstSubmitQcDate":"2006-05-08","studyFirstPostDateStruct":{"date":"2006-05-10","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-04-20","resultsFirstSubmitQcDate":"2016-06-14","resultsFirstPostDateStruct":{"date":"2016-07-27","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-07-30","lastUpdatePostDateStruct":{"date":"2016-09-07","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Heather Wakelee","investigatorTitle":"Associate Professor of Medicine (Oncology)","investigatorAffiliation":"Stanford University"},"leadSponsor":{"name":"Stanford University","class":"OTHER"},"collaborators":[{"name":"Eli Lilly and Company","class":"INDUSTRY"},{"name":"Genentech, Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"A multi-center study of bevacizumab in combination with gemcitabine and carboplatin as treatment for newly-diagnosed advanced non-small cell lung cancer (NSCLC).","detailedDescription":"This is a open-label, phase 2, single-arm, multi-center study of bevacizumab combined with gemcitabine and carboplatin. This treatment is for newly-diagnosed advanced non-small cell lung cancer (NSCLC), excluding squamous cell carcinoma. All subjects will receive 15 mg/kg bevacizumab every 3 weeks cycle, 1000 mg/m² of gemcitabine on day 1 and 8 every 3 weeks cycle and carboplatin (AUC= 5 ) every 3 weeks. Carboplasm will be administered 1 hour prior to the gemcitabine infusion, bevacizumab will be administered 1 hour following chemotherapy infusion.\n\nSubjects will receive a maximum of 6 cycles of chemotherapy, but treatment with bevacizumab may continue as long as patients have no evidence of progressive disease and no significant treatment-related toxicities."},"conditionsModule":{"conditions":["Lung Cancer","Non-small Cell Lung Cancer (NSCLC)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":48,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Bevacizumab + carboplatin + gemcitabine","type":"EXPERIMENTAL","description":"Bevacizumab in combination with carboplatin and gemcitabine:\n\n•Carboplatin, administered IV at area under the curve (AUC) of 5, every 3 weeks on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles.\n\nCarboplatin was administered before the gemcitabine infusion:\n\n•Gemcitabine, administered 1000 mg/m² IV on days 1 and 8 of each 3-week cycle (twice per cycle) for up to 6 cycles\n\nBevacizumab was administered 1 hour after end of all chemotherapy infusions:\n\n•Bevacizumab was administered 15 mg/kg IV on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles in combination with chemotherapy, then continuing until evidence of progressive disease or significant treatment-related toxicity","interventionNames":["Drug: Bevacizumab","Drug: Gemcitabine","Drug: Carboplatin"]}],"interventions":[{"type":"DRUG","name":"Bevacizumab","description":"Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody","armGroupLabels":["Bevacizumab + carboplatin + gemcitabine"],"otherNames":["Avastin","C225","rhuMAb-VEGF"]},{"type":"DRUG","name":"Gemcitabine","description":"Nucleoside analog","armGroupLabels":["Bevacizumab + carboplatin + gemcitabine"],"otherNames":["Gemzar"]},{"type":"DRUG","name":"Carboplatin","description":"Alkylating agent","armGroupLabels":["Bevacizumab + carboplatin + gemcitabine"],"otherNames":["Paraplatin","CBDCA"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-free Survival (PFS)","description":"Median progression-free survival (PFS) was assessed as the time to disease progression; toxicity requiring treatment discontinuation; or death.","timeFrame":"18 months"}],"secondaryOutcomes":[{"measure":"Response Rate (CR + PR + SD)","description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions, by computed tomography (CT); bone scan; positron emission tomography (PET) scan; and/or magnetic resonance imaging (MRI) as necessary to assess diseasE\n\nResponse determined as the number of subjects with any clinical response (CR + PR + SD) per RECIST criteria.\n\n* Complete Response (CR) = disappearance of all target lesions\n* Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions\n* Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, or appearance of new cancer lesions\n* Stable Disease (SD): No significant effect, does not meet criteria for PR or PD.","timeFrame":"6 weeks"},{"measure":"Overall Survival (OS)","description":"To evaluate the safety of the combination regimen.","timeFrame":"36 months"},{"measure":"Partial Response (PR)","description":"Number of subjects with PR per RECIST criteria","timeFrame":"6 weeks"},{"measure":"Complete Response (CR)","description":"Number of subjects with CR per RECIST criteria","timeFrame":"6 weeks"},{"measure":"Stable Disease (SD)","description":"Number of subjects with SD per RECIST criteria","timeFrame":"6 weeks"},{"measure":"Time-to-First Event","description":"Median time-to-first event, with events defined as disease progression, death, or toxicity requiring drug discontinuation","timeFrame":"18 months"},{"measure":"Overall Survival (OS) at 12 Months","description":"Number of subjects surviving 1 year after treatment initiation","timeFrame":"12 months"},{"measure":"Overall Survival (OS) at 24 Months","description":"Number of subjects surviving 2 years after treatment initiation","timeFrame":"24 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria :\n\n* Age 18 or higher\n* Life expectancy of at least 3 months\n* ECOG Performance status 0 to 1\n* Advanced stage non-small cell lung cancer, NSCLC, Stage IIIB with malignant pleural effusion or Stage 4, excluding squamous cell histology, with measurable or evaluable disease\n* No prior systemic therapy for advanced NSCLC (prior therapy for early stage disease with one regimen is acceptable if it was completed at least 6 months prior to study entry)\n* Palliative radiotherapy to painful bony metastases is permitted prior to study entry if completed prior to initiation of study treatment, and there are no residual sequelae of therapy such as bone marrow suppression\n* Willingness to use appropriate contraception to avoid pregnancy during the study\n* Leukocytes ≥ 3,000/µL\n* Absolute neutrophil count ≥ 1,500/ µL\n* Platelets ≥ 100,000/ µL\n* Total bilirubin within normal institutional limits\n* AST(SGOT)/ALT(SGPT) ≤ 2.5 x institutional upper limit of normal\n* Creatinine: Within normal institutional limits\n* Creatinine clearance ≥ 60 mL/min/1.73 m² for patients with creatinine levels above institutional normal\n* Ability to sign informed consent\n\nExclusion Criteria:\n\n* Prior systemic treatment for advanced NSCLC (one prior regimen of up to 4 cycles of neoadjuvant or adjuvant therapy for early stage disease will be allowed, if completed at least 6 months prior to study entry)\n* Known brain metastases\n* Prior treatment with bevacizumab\n* History of allergic reactions\n* Sensitivity attributed to compounds of similar chemical or biologic composition to bevacizumab\n* Current, recent (within 4 weeks of the first infusion of this study), or planned participation in any other experimental drug study\n* Concomitant chemotherapy, radiotherapy, or investigational agents\n* Evidence of bleeding diathesis\n* Coagulopathy\n* Use of anti-coagulant agents including warfarin, heparin, aspirin, NSAIDs\n* Pregnant\n* Lactating\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study\n* Minor surgical procedures within 7 days prior to day 0\n* Fine needle aspirations within 7 days prior to day 0\n* Core biopsies within 7 days prior to day 0\n* Urine protein: creatinine ratio ≥ 1.0 at screening\n* History of abdominal fistula within 6 months prior to Day 0\n* Gastrointestinal perforation within 6 months prior to Day 0\n* Intra-abdominal abscess within 6 months prior to Day 0\n* Serious, non-healing wound\n* Ulcer\n* Bone fracture\n* Lung carcinoma of squamous cell histology\n* Any histology in close proximity to a major vessel\n* Significant cavitation as assessed by treating investigator in consultation with an attending radiologist\n* History of hemoptysis (bright red blood of 1/2 teaspoon or more)\n* Blood pressure of \\> 150/100 mmHg\n* Unstable angina\n* New York Heart Association (NYHA) Grade 2 or greater congestive heart failure\n* History of myocardial infarction within 6 months\n* History of stroke within 6 months\n* Clinically significant peripheral vascular disease\n* Psychiatric illness/social situations that would limit compliance with study requirements\n* Another active malignancy except for non-melanoma skin cancers\n* Inability to comply with study and/or follow-up procedures","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Heather A Wakelee, MD","affiliation":"Stanford University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"VA Palo Alto Healthcare System","city":"Palo Alto","state":"California","zip":"94304-1290","country":"United States","geoPoint":{"lat":37.44188,"lon":-122.14302}},{"facility":"Santa Clara Valley Medical Center","city":"San Jose","state":"California","zip":"95128","country":"United States","geoPoint":{"lat":37.33939,"lon":-121.89496}},{"facility":"Stanford University School of Medicine","city":"Stanford","state":"California","zip":"94305","country":"United States","geoPoint":{"lat":37.42411,"lon":-122.16608}}]},"referencesModule":{"references":[{"pmid":"20881641","type":"RESULT","citation":"Clement-Duchene C, Krupitskaya Y, Ganjoo K, Lavori P, McMillan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo MS, Colevas AD, Wakelee HA. A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010 Nov;5(11):1821-5. doi: 10.1097/JTO.0b013e3181f1d23c."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Bevacizumab + Carboplatin + Gemcitabine","description":"Bevacizumab in combination with carboplatin and gemcitabine\n\nBevacizumab was administered 15 mg/kg IV on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles in combination with chemotherapy, then continuing until evidence of progressive disease or significant treatment-related toxicity Gemcitabine, administered 1000 mg/m2 IV on days 1 and 8 of each 3-week cycle (twice per cycle) for up to 6 cycles Carboplatin, administered IV at area under the curve (AUC) of 5, every 3 weeks on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles\n\nCarboplatin was administered before gemcitabine infusion.\n\nBevacizumab was administered 1 hour after end of all chemotherapy infusions.\n\nBevacizumab: Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody\n\nGemcitabine: Nucleoside analog\n\nCarboplatin: Alkylating agent"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Enrollment","numSubjects":"48"}]},{"type":"Treatment Initiation","achievements":[{"groupId":"FG000","comment":"One participant died before receiving therapy, not included in analysis","numSubjects":"47"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"47"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Bevacizumab + Carboplatin + Gemcitabine","description":"Treatment provided in 3-week cycles:\n\n* 15 mg/kg bevacizumab Day 1 of each cycle\n* 1000 mg/m2 gemcitabine Days 1 and 8 of each cycle\n* Carboplatin (AUC of 5 every 3 weeks)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"47"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59","lowerLimit":"35","upperLimit":"81"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"25"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"22"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"42"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"10"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"3"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"29"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"4"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) performance status","description":"ECOG performance status\n\n* 0 = Fully active, able to carry on all pre-disease performance without restriction\n* 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg, light house work, office work\n* 2 = Unable to work, must sit or lie \\> 50% waking hours\n* 3 = Capable of limited selfcare; confined to bed or chair \\> 50% waking hours\n* 4 = Completely disabled; cannot carry on any selfcare; totally confined to bed/chair\n* 5 = Deceased","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"ECOG 0","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]},{"title":"ECOG 1","categories":[{"measurements":[{"groupId":"BG000","value":"44"}]}]}]},{"title":"Smoking Status","description":"Smoking status based on self-declaration between:\n\n* Never a smoker (\\< 100 cigarettes in lifetime)\n* Quit and not currently a smoker\n* Currently a smoker.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Never a smoker","categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}]},{"title":"Has stopped smoking (ex-smoker)","categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}]},{"title":"Currently a smoker","categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}]}]},{"title":"Non-small Cell Lung Cancer (NSCLC) Histology","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Adenocarcinoma","categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}]},{"title":"Bronchioloalveolar carcinoma (BAC)","categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}]},{"title":"NSCLC not otherwise specified","categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}]}]},{"title":"Non-small Cell Lung Cancer Stage","description":"During the time of the trial patients with a malignant pleural effusion as only site of metastases were considered stage III-B (AJCC 6th edition). They were treated the same as stage IV (metastatic). Thus all patients included in this trial had advanced stage NSCLC and if staged under current staging criteria (AJCC 7th edition) all would be considered stage IV (metastatic).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"NSCLC Stage III-B","categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}]},{"title":"NSCLC Stage IV","categories":[{"measurements":[{"groupId":"BG000","value":"39"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS)","description":"Median progression-free survival (PFS) was assessed as the time to disease progression; toxicity requiring treatment discontinuation; or death.","populationDescription":"Includes all subjects who initiated treatment","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"months","timeFrame":"18 months","groups":[{"id":"OG000","title":"Bevacizumab + Carboplatin + Gemcitabine","description":"Treatment provided in 3-week cycles:\n\n* 15 mg/kg bevacizumab Day 1 of each cycle\n* 1000 mg/m2 gemcitabine Days 1 and 8 of each cycle\n* Carboplatin (AUC of 5 every 3 weeks)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","lowerLimit":"7.8","upperLimit":"17.9"}]}]}]},{"type":"SECONDARY","title":"Response Rate (CR + PR + SD)","description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions, by computed tomography (CT); bone scan; positron emission tomography (PET) scan; and/or magnetic resonance imaging (MRI) as necessary to assess diseasE\n\nResponse determined as the number of subjects with any clinical response (CR + PR + SD) per RECIST criteria.\n\n* Complete Response (CR) = disappearance of all target lesions\n* Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions\n* Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, or appearance of new cancer lesions\n* Stable Disease (SD): No significant effect, does not meet criteria for PR or PD.","populationDescription":"Includes all subjects who initiated treatment","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"6 weeks","groups":[{"id":"OG000","title":"Bevacizumab + Carboplatin + Gemcitabine","description":"Treatment provided in 3-week cycles:\n\n* 15 mg/kg bevacizumab Day 1 of each cycle\n* 1000 mg/m2 gemcitabine Days 1 and 8 of each cycle\n* Carboplatin (AUC of 5 every 3 weeks)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"To evaluate the safety of the combination regimen.","populationDescription":"Includes all subjects who initiated treatment","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"36 months","groups":[{"id":"OG000","title":"Bevacizumab + Carboplatin + Gemcitabine","description":"Treatment provided in 3-week cycles:\n\n* 15 mg/kg bevacizumab Day 1 of each cycle\n* 1000 mg/m2 gemcitabine Days 1 and 8 of each cycle\n* Carboplatin (AUC of 5 every 3 weeks)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","lowerLimit":"10.0","upperLimit":"16.5"}]}]}]},{"type":"SECONDARY","title":"Partial Response (PR)","description":"Number of subjects with PR per RECIST criteria","populationDescription":"Includes all subjects who initiated treatment","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"6 weeks","groups":[{"id":"OG000","title":"Bevacizumab + Carboplatin + Gemcitabine","description":"Treatment provided in 3-week cycles:\n\n* 15 mg/kg bevacizumab Day 1 of each cycle\n* 1000 mg/m2 gemcitabine Days 1 and 8 of each cycle\n* Carboplatin (AUC of 5 every 3 weeks)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}]},{"type":"SECONDARY","title":"Complete Response (CR)","description":"Number of subjects with CR per RECIST criteria","populationDescription":"Includes all subjects who initiated treatment","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"6 weeks","groups":[{"id":"OG000","title":"Bevacizumab + Carboplatin + Gemcitabine","description":"Treatment provided in 3-week cycles:\n\n* 15 mg/kg bevacizumab Day 1 of each cycle\n* 1000 mg/m2 gemcitabine Days 1 and 8 of each cycle\n* Carboplatin (AUC of 5 every 3 weeks)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}]},{"type":"SECONDARY","title":"Stable Disease (SD)","description":"Number of subjects with SD per RECIST criteria","populationDescription":"Includes all subjects who initiated treatment","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"6 weeks","groups":[{"id":"OG000","title":"Bevacizumab + Carboplatin + Gemcitabine","description":"Treatment provided in 3-week cycles:\n\n* 15 mg/kg bevacizumab Day 1 of each cycle\n* 1000 mg/m2 gemcitabine Days 1 and 8 of each cycle\n* Carboplatin (AUC of 5 every 3 weeks)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}]}]},{"type":"SECONDARY","title":"Time-to-First Event","description":"Median time-to-first event, with events defined as disease progression, death, or toxicity requiring drug discontinuation","populationDescription":"Includes all subjects who initiated treatment","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"18 months","groups":[{"id":"OG000","title":"Bevacizumab + Carboplatin + Gemcitabine","description":"Treatment provided in 3-week cycles:\n\n* 15 mg/kg bevacizumab Day 1 of each cycle\n* 1000 mg/m2 gemcitabine Days 1 and 8 of each cycle\n* Carboplatin (AUC of 5 every 3 weeks)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.4","lowerLimit":"4.8","upperLimit":"7.9"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) at 12 Months","description":"Number of subjects surviving 1 year after treatment initiation","populationDescription":"Includes all subjects who initiated treatment","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"12 months","groups":[{"id":"OG000","title":"Bevacizumab + Carboplatin + Gemcitabine","description":"Treatment provided in 3-week cycles:\n\n* 15 mg/kg bevacizumab Day 1 of each cycle\n* 1000 mg/m2 gemcitabine Days 1 and 8 of each cycle\n* Carboplatin (AUC of 5 every 3 weeks)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) at 24 Months","description":"Number of subjects surviving 2 years after treatment initiation","populationDescription":"Includes all subjects who initiated treatment","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"24 months","groups":[{"id":"OG000","title":"Bevacizumab + Carboplatin + Gemcitabine","description":"Treatment provided in 3-week cycles:\n\n* 15 mg/kg bevacizumab Day 1 of each cycle\n* 1000 mg/m2 gemcitabine Days 1 and 8 of each cycle\n* Carboplatin (AUC of 5 every 3 weeks)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"6 weeks","description":"All assessments were taken after every two cycles. Evaluations were taken the first 6 weeks, then every 3 weeks","eventGroups":[{"id":"EG000","title":"Bevacizumab + Carboplatin + Gemcitabine","description":"Treatment provided in 3-week cycles:\n\n* 15 mg/kg bevacizumab Day 1 of each cycle\n* 1000 mg/m2 gemcitabine Days 1 and 8 of each cycle\n* Carboplatin (AUC of 5 every 3 weeks)","seriousNumAffected":28,"seriousNumAtRisk":47,"otherNumAffected":17,"otherNumAtRisk":47}],"seriousEvents":[{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":47}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Confusion","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Pneumonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":47}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":47}]},{"term":"Hemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":47}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":47}]},{"term":"Hemorrahage","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Nose","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Platetes","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Hypotension","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Leukocytes","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Hyponatreamia due to SIADH","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"SIADH- syndrome of inappropriate antidiuretic hormone","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":47}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Possible Pneumonia","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Bilirubin","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"hyperbilirubinemia","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Hematoma","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Liver Hemorrhage","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Pulmonary Respiratory Distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]}],"otherEvents":[{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":47}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":47}]},{"term":"Confusion","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":47}]},{"term":"Leukocytes","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":47}]},{"term":"Transaminitis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Pain","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Chest","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Neutrophilis/Granolocytes","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]},{"term":"Creatinine","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE (3.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":47}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Heather A Wakelee, MD, Associate Professor of Medicine (Oncology)","organization":"Stanford University Medical Center","email":"hwakelee@stanford.edu","phone":"650-498-6000"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D008175","term":"Lung Neoplasms"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068258","term":"Bevacizumab"},{"id":"D000068818","term":"Cetuximab"},{"id":"D000093542","term":"Gemcitabine"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}